Xin Jing Bao·2025-10-27 11:05Core Insights - BioPark in Beijing Economic-Technological Development Area is becoming a global hub for pharmaceutical and health collaboration, attracting major multinational companies and local innovators [1][2][3] - AstraZeneca has announced a $2.5 billion investment to establish its sixth global strategic R&D center in Beijing, highlighting the area's appeal for international pharmaceutical investments [1][2] - The park covers approximately 5.5 square kilometers and includes four functional zones to support various stages of pharmaceutical development, from R&D to large-scale production [1][2] Group 1 - BioPark is home to multinational giants like AstraZeneca, Eli Lilly, Pfizer, Bayer, and Medtronic, with upcoming projects from Johnson & Johnson, Philips, and Bristol-Myers Squibb [1] - The park's design includes extensive green spaces, making up over half of its area, and aims to create a friendly environment for talent through a slow-moving system connecting the functional zones [2] - The Beijing Economic-Technological Development Area plans to enhance BioPark's infrastructure by integrating education, research, and medical resources, including an AI application pilot base and a world-class health education base [2][3] Group 2 - Over the past year, BioPark has transitioned from concept to reality, receiving support from global partners and attracting participation from 62 renowned international firms in its planning [3] - The development plan for BioPark is set to be accelerated, with a focus on creating a high ground for the pharmaceutical industry, a startup hub for medical talent, and a demonstration area for AI applications [3]